Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 21, 2019
Event Date: January 21, 2019 (Earliest event reported)
Business Context: The Company is an emerging growth company incorporated in Nevada, trading on NASDAQ under the symbol IMNB. This filing serves as a Regulation FD disclosure regarding the commencement of using a specific Investor Presentation for prospective investors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a non-financial event (the use of an investor presentation) and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The material change disclosed is the operational decision to begin utilizing a specific Investor Presentation for investor communications as of January 21, 2019.
Guidance, Outlook, and Risks
Management Commentary: The Company attached an Investor Presentation (Exhibit 99.1) to this report. Management explicitly states that the information in this report and the attached exhibit is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. Consequently, it is not subject to the liabilities of that section nor incorporated by reference into other filings.
Risks and Contingencies: The filing includes standard disclaimers regarding the non-filing status of the attached presentation to limit liability. No specific operational risks or contingencies are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the content of the attached Exhibit 99.1 (Investor Presentation) for specific business updates, as the 8-K text only references its existence.
- Confirm the Company's status as an "emerging growth company" and its implications for financial reporting standards.
- Note that the information provided is not "filed" under the Exchange Act and carries different liability standards than a formal 10-K or 10-Q.
- Review subsequent filings for actual financial performance data, as this document contains none.